| Literature DB >> 29654264 |
Gaurav Goyal1, Adam C Bartley2, Shealeigh Funni3, Jonathan Inselman3, Nilay D Shah3, Ariela L Marshall4, Aneel A Ashrani4, Prashant Kapoor4, Urshila Durani4, Shahrukh K Hashmi4, Mustaqeem A Siddiqui4, Francis K Buadi4, Ronald S Go4, Robert A Kyle4, Shaji Kumar4, Wilson I Gonsalves4.
Abstract
Solitary plasmacytomas are uncommon plasma cell disorders, which may present as a single bone lesion (P-bone) or extramedullary plasmacytoma (P-EM). There is a paucity of large studies analyzing prognostic factors and outcomes of plasmacytomas. While the treatment of choice is radiation therapy (RT), there is a lack of data evaluating optimal RT dose. In this study, we sought to answer these questions by utilizing the National Cancer Database plasmacytoma data from 2000 to 2011. A total of 5056 patients were included in the study (median age 62 years; range 52-72). To obtain a pure plasmacytoma cohort, potential multiple myeloma patients were excluded from the study (bone marrow involvement, systemic chemotherapy use). P-bone constituted 70% of the patients. The median overall survival (OS) of P-EM was significantly longer than P-bone (132 vs. 85 months), and for soft/connective tissue it was worse than remainder of P-EM (82 vs. 148 months). On multivariable analysis, factors associated with worse OS included older age (≥65), presence of P-bone, and treatment with a radiation dose <40 Gy.Entities:
Mesh:
Year: 2018 PMID: 29654264 PMCID: PMC6522261 DOI: 10.1038/s41375-018-0099-8
Source DB: PubMed Journal: Leukemia ISSN: 0887-6924 Impact factor: 11.528